Silo Pharma, Inc (OTCQB:SILO) CEO Eric Weisblum talks to Proactive about the developmental stage biopharmaceutical company's latest license agreement with the University of Maryland to treat multiple sclerosis and other neuroinflammatory pathology.
Weisblum will be presenting at Proactive's One2One Investor Forum on February 23 at 1pm ET.